AREV Life Sciences Global Corp. With a focus on phytomedicinalization and commercialization of unique botanicals and marine species, AREV aims to revolutionize healthcare. The company's pipeline includes a range of products and services, such as therapeutic human nutrition and ingredient processing.

AREV is committed to addressing pandemic diseases, malnutrition, and neglected chronic comorbidities through novel therapeutic approaches. AREV is at the forefront of developing small molecule antivirals and is actively involved in the field of human nutrition. They are currently working on the development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of COVID-19.

Backed by their Scientific Advisory Board and strategic collaborations, including partnerships with Voynich Biosciences, Oregon State University (OSU), and the Institute of Human Virology, AREV is positioned as a leader in the industry. AREV's core competency lies in extraction, allowing them to produce high-quality ingredients and compounds for their pipeline of products. They prioritize ethical sourcing and fair workplace culture, while also addressing racial and gender disparities in access to essential medicine.

With a dedication to global citizenship and equitable collaborations, AREV is committed to making a positive impact on the world of healthcare